All
Vector Laboratories Acquires Quanta BioDesign
Vector Laboratories announced the acquisition of Quanta BioDesign on July 17, 2023, which further expands the former’s portfolio of bioconjugation linkers and dyes, as well as its manufacturing sector, according to the press release.
Westlake Village BioPartners Announces $450 Million Venture Capital Funding Pool
Westlake’s third fund of $450 million will be used to grow early stage biotechnology companies.
metabion Expands Oligonucleotide Production Capacity in Germany
German manufacturer metabion is conducting a multi-million euro expansion of its oligonucleotide manufacturing capacity in Munich East.
Moving Closer to Dynamic Drug Development through Automated Solutions
There are solutions on the horizon that will help overcome the current bottlenecks and other challenges that are occurring in early drug development.
FDA Converts Eisai Alzheimer’s Treatment to Traditional Approval
Eisai’s lecanemab-irmb was converted from an accelerated approval to a traditional approval.
EMA Reviews GLP-1 Receptor Agonists for Self-Harm Risk
The agency is reviewing the medicines after receiving reports of self-injury and suicidal thoughts in patients using the type 2 diabetes treatments.
EMA Aims to Develop Guideline for mRNA Vaccines
EMA looks to focus on mRNA vaccines because their classification depends on the target and/or whether they are obtained chemically or biologically.
Biosynth Acquires Celares for Growing Conjugate Vaccine Market
The acquisition will continue to strengthen the area of conjugate vaccines and bioconjugate drugs and will expand Biosynth’s capabilities from good manufacturing practice facilities located in Berlin, Germany.
Large Clinical Trial Supports Alzheimer Drug Full Approval
FDA's approval of Leqembi paves the way for wider coverage of the drug by Medicare and establishes a process for further clinical testing and evaluation of treatments for this widespread, debilitating condition
Thermo Fisher Scientific Agrees to Acquire CorEvitas
The transaction is expected to be completed by the end of 2023 where CorEvitas will become a part of Thermo Fisher’s Laboratory Products and Biopharma Services segment.
Caribou Biosciences Receives $25 Million Equity Investment from Pfizer
In addition, Caribou will maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Camena Bioscience Raises $10 Million to Pursue DNA Synthesis Technology
Camena Bioscience has completed $10 million in Series A financing on the back of growing demand for DNA synthesis.
Thermo Fisher Scientific Releases Tumoroid Culture Medium Kit
Thermo Fisher Scientific’s new tumoroid culture medium kit is designed to help cancer researchers better model the disease.
Eurofins Genomics Blue Heron Launches In-Vitro Transcription mRNA Synthesis Service
Eurofins Genomics Blue Heron’s novel mRNA synthesis service is designed for customizable applications.
Chime Biologics Forms mAb Development and Manufacturing Deal with Leads Biolabs and BeiGene
Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.
FDA Approves BioMarin’s Roctavian, the First Gene Therapy for Treating Severe Hemophilia A
FDA has approved Roctavian (valoctocogene roxaparvovec-rvox), a gene therapy from BioMarin Pharmaceutical for treating severe hemophilia A in adults.
Donaldson Company Acquires Univercells Technologies for €136 Million
Donaldson Company’s €136 million (US$148 million) acquisition of Univercells is designed to broaden its portfolio of biomanufacturing solutions.
Tower Cold Chain Expands to American Center of Excellence
Tower Cold Chain will soon open its new headquarters in Philadelphia.
GSK Acquires BELLUS Health
This arrangement was approved by the shareholders at BELLUS on June 16, 2023, according to a company press release.
FDA Approves Pfizer Human Growth Hormone Analog
FDA approved Pfizer’s once-weekly human growth hormone analog for treatment of growth failure in pediatric patients.
NCI Launches Persistent Poverty Initiative
The persistent poverty initiative aims to fight the cumulative effects of persistent poverty on cancer outcomes.
FDA Approves UCB Generalized Myasthenia Gravis Treatment
UCB’s rozanolixizumab-noli is approved for treatment of generalized myasthenia gravis in certain adult patient groups.
Gene Therapy for Duchenne Muscular Dystrophy Approved by FDA
The agency approved Elevidys to treat pediatric patients four through five years of age with Duchenne muscular dystrophy.
Maurice Michel of Sweden Wins 2023 Eppendorf Award for Young European Investigators
The prestigious award, worth €20,000 (US$22,000), goes to Maurice Michel of the Science for Life Laboratory at Karolinska Institutet, Stockholm, Sweden.
SCTbio and Cyto-care Collaborate to Improve Cell Therapy Cryopreservation
The companies hope address the need for efficient collection, cryopreservation, quality control, and logistics capabilities of leukapheresis materials to support various aspects of the cell therapy workflow.
Oliva Therapeutics to Partner with Rio Biopharmaceuticals
This collaboration is the first commercialization into the United States and Canadian markets for Rio Biopharmaceuticals.
Sanofi Consumer Healthcare Opens Suggestion Portal
Sanofi’s Open Innovation Portal is designed to promote community feedback and propose novel solutions to various problems in the healthcare landscape.
SandboxAQ Launches Molecular Simulation Division
Sandbox AQ’s molecular simulation division is collaborating with companies like AstraZeneca and Sanofi to develop novel treatments for various disorders.
FDA Releases Draft Guidance for Section 505G of Food, Drug, and Cosmetic Act
The guidance describes the CDER formal dispute resolution (FDR) procedures for eligible requestors or sponsors that wish to appeal a scientific and/or medical issue related to a final order.
Andelyn Biosciences Opens New CGT Manufacturing Headquarters
The new headquarters located in Columbus, Ohio, more than triples Andelyn Biosciences’ footprint to meet growing demand for CGT services.
